US OptionsDetailed Quotes

IONS241220C40000

Watchlist

0.20
-0.15-42.86%

15min DelayClose Dec 3 16:00 ET

0.30High0.20Low

Ionis Pharmaceuticals Stock Discussion

Jaguar8

Apr 7 23:52

$Ionis Pharmaceuticals (IONS.US)$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”

Moomoo AI

Mar 17 10:16

Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Moomoo AI

Feb 29 08:12

Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.

Press Release: Ionis Announces New Chief Global Product Strategy Officer to Lead Next Phase of Commercial Growth

Moomoo AI

Feb 19 13:10

Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.

Insider Sellers Might Regret Selling Ionis Pharmaceuticals Shares at a Lower Price Than Current Market Value

Moomoo AI

Dec 29, 2023 02:22

Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Bull Market Watch

Apr 26, 2023 07:04

One Of The Best Pharmaceutical Stocks Just Got FDA Approval | Big Robust Pipeline Ahead

$Ionis Pharmaceuticals (IONS.US)$

One Of The Best Pharmaceutical Stocks Just Got FDA Approval | Big Robust Pipeline Ahead

From YouTube

BioPharm Insight US

Apr 24, 2023 11:52

Columns Weekly FDA Drug Pipeline Calendar (April 24 - April 28)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...

Moomoo Breakfast US

Sep 23, 2022 07:59

Columns Today's Pre-Market Stock Movers: QCOM, BA, ROKU, AZN and More

Gapping up
In reaction to earnings/guidance:
• $CalAmp (CAMP.US)$ +0.6%
Other news:
• $Cano Health (CANO.US)$ +6.1% ( $Humana (HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics (CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial (LPLA.US)$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona (XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +2.9% (tr...

No comment yet